Device Trial Radar · NCT01533038
BPH-6: Comparison of the UroLift System to TURP for Benign Prostatic Hyperplasia
Last checked: Nov 19, 2026Latest source record: Dec 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Feb 2012
Primary completion
Oct 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- NeoTract, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 15, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the UroLift System Treatment to Transurethral Resection of the Prostate (TURP) in improving a patient's overall quality of life, while evaluating healthcare expenditures associated with each therapy.
Conditions
- Benign Prostatic Hyperplasia
Interventions
UroLift SystemDevice
The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
Transurethral Resection of the ProstateProcedure
Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder Analysis: A Subject is a Responder at the 12 Month Follow-up Time Point if All 6 Thresholds of the BPH-6 Endpoint Are MetTime frame: Month 12
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Herlev Hospital
Herlev, Denmark
PAN Klinik
Cologne, Germany
University Hospital Freiburg
Freiburg im Breisgau, Germany
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.